论文部分内容阅读
目的:评价盐酸拓扑替康(金喜素)联合顺铂治疗小细胞肺癌(SCLC)的疗效和不良反应。方法:金喜素1·2mg/(m2·d)静滴第1~5天;顺铂20~30mg/(m2·d),静滴,第1~3天,21天为1疗程,2~3个疗程后判定疗效及不良反应。结果:CR4例,PR12例,SD6例,PD3例,总有效率为64%。主要不良反应为骨髓抑制和胃肠道反应。结论:金喜素联合顺铂疗效较好,毒性可耐受,可作为SCLC一线或二线用药。
Objective: To evaluate the efficacy and adverse reactions of Topotecan Hydrochloride combined with cisplatin in the treatment of small cell lung cancer (SCLC). Methods: Gemcitabine was intravenously administered for 1 to 5 days at a dose of 1 · 2 mg / (m2 · d), followed by intravenous infusion of 20 to 30 mg / (m2 · d) for 1 to 3 days and 21 days for 1 course of treatment. After a course of treatment to determine efficacy and adverse reactions. Results: CR4 cases, PR12 cases, SD6 cases, PD3 cases, the total effective rate was 64%. The main adverse reactions were myelosuppression and gastrointestinal reactions. Conclusion: The combination of gold and cisplatin is effective and tolerable. It can be used as first-line or second-line SCLC.